Tumor Biology

, Volume 37, Issue 7, pp 9209–9219 | Cite as

Pre-treatment VD levels and VDR receptors as potential predictors of occurrence and overall survival in paediatric patients with solid tumours—a single institution pilot study

  • Julie Bienertová-Vašků
  • Klára Drábová
  • Filip Zlámal
  • Josef Tomandl
  • Michal Kýr
  • Zbyněk Šplíchal
  • Jaroslav Štěrba
Original Article

Abstract

Recently, vitamin D has been recognized as an important player in the immune system, and multiple studies suggested its involvement in cancer, too. The aims of this study were to investigate selected single nucleotide polymorphisms (SNPs) in the VDR gene, BsmI (rs1544410; A > G), FokI (rs 2228570; C > T), TaqI (rs731236; T > C), ApaI (rs 7975232; C > T) and Cdx-2 (rs11568820; A > G), and to evaluate their possible predictive role for outcomes in patients with paediatric solid tumours. A total of 111 children with paediatric solid tumours were enrolled at the Department of Paediatric Oncology, University Hospital Brno (Brno, Czech Republic) along with a control population of 787 adults; all study subjects were available for genotyping of selected SNPs, and the prediagnostic levels of 25-hydroxycholecalciferol (25(OH)D3) and 1,25-dihydroxycholecalciferol (1,25(OH)2D3) were measured in the cases, too. In FokI, the heterozygote CT genotype was weakly associated with a decreased risk of paediatric solid cancer occurrence 0.82 (0.53–1.28), while the CC genotype was associated with a decreased risk of 0.58 (0.30–1.09), p = 0.09. The 1,25(OH)2D3 prediagnostic levels were indicative of the overall survival in the cases (β = −0.012, HR 0.988, 95 % CI (0.978–0.998), while higher prediagnostic levels of 1,25(OH)2D3 were associated with a statistically significant increase in overall mortality. We observed multiple effects of the alleles of the investigated polymorphisms and of 1,25(OH)2D3 on overall survival, regardless of the underlying disease.

Keywords

Vitamin D Childhood cancer Overall survival VDR Gene SNP 

Notes

Acknowledgments

Each author has made an important scientific contribution to the study and has assisted with the drafting or revising of the manuscript in accordance with the definition of an author as stated by the International Committee of Medical Journal Editors. This study was supported by the CETOCOEN PLUS project and the RECETOX infrastructure that is supported by the Czech Ministry of Education (LM2011028).

Compliance with ethical standards

This study, including the consent protocol, was approved by a local ethics committee in compliance with the Helsinki Declaration. Written informed consent was obtained from all participants.

Conflicts of interest

None

References

  1. 1.
    Giovannucci E. Vitamin D, status and cancer incidence and mortality. Adv Exp Med Biol. 2008;624:31–42.CrossRefPubMedGoogle Scholar
  2. 2.
    Shui I, Giovannucci E. Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol. 2014;810:33–51.PubMedGoogle Scholar
  3. 3.
    Campbell FC, Xu H, El-Tanani M, Crowe P, Bingham V. The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem Pharmacol. 2010;79:1–9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Toell A, Polly P, Carlberg C. All natural DR3-type vitamin D response elements show a similar functionality in vitro. Biochem J. 2000;352 Pt 2:301–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Pike JW, Meyer MB. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D 3. Endocrinol Metab Clin North Am. 2010;39:255–69.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ryan JW, Anderson PH, Morris HA. Pleiotropic activities of vitamin D receptors—adequate activation for multiple health outcomes. Clin Biochem Rev. 2015;36:53–61.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Slattery ML. Vitamin D, receptor gene (VDR) associations with cancer. Nutr Rev. 2007;65:S102–4.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol. 2000;14:401–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Smith MA, Seibel NL, Altekruse SF, Ries LAG, Melbert DL, O’Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. JCO. 2010;28:2625–34.CrossRefGoogle Scholar
  10. 10.
    Li L, Shang F, Zhang W, Zhang C, Li J, Wang C, et al. Role of vitamin D receptor gene polymorphisms in pancreatic cancer: a case-control study in China. Tumour Biol. 2015;36(6):4707–14.Google Scholar
  11. 11.
    Mishra DK, Wu Y, Sarkissyan M, Sarkissyan S, Chen Z, Shang X, et al. Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS ONE. 2013;8:e57967.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gogas Yavuz D, Keskin L, Kıyıcı S, Sert M, Yazıcı D, Sahin I, et al. Vitamin D receptor gene BsmI, FokI, ApaI, TaqI polymorphisms and bone mineral density in a group of Turkish type 1 diabetic patients. Acta Diabetol. 2011;48:329–36.CrossRefPubMedGoogle Scholar
  13. 13.
    Dickinson JL, Perera DI, van der Mei AF, Ponsonby A-L, Polanowski AM, Thomson RJ, et al. Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. Mult Scler. 2009;15:563–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Shao T, Klein P, Grossbard ML. Vitamin D and breast cancer. Oncologist. 2012;17:36–45.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ilhan M, Toptas-Hekimoglu B, Yaylim I, Turgut S, Turan S, Karaman O, et al. Investigation of the vitamin D receptor polymorphisms in acromegaly patients. BioMed Res Int. 2015;2015:e625981.CrossRefGoogle Scholar
  16. 16.
    Reichrath J, Friedrich M, Tilgen W. Vitamin D analogs in cancer prevention and therapy. Germany: Springer Science & Business Media; 2003.CrossRefGoogle Scholar
  17. 17.
    Chen X, Pappo A, Dyer MA. Pediatric solid tumor genomics and developmental pliancy. Oncogene [Internet]. 2015 [cited 2015 Aug 18]; Available from: http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2014474a.html
  18. 18.
    Kline NE, Sevier N. Solid tumors in children. J Pediatr Nurs. 2003;18:96–102.CrossRefPubMedGoogle Scholar
  19. 19.
    Bassett EA, Wallace VA. Cell fate determination in the vertebrate retina. Trends Neurosci. 2012;35:565–73.CrossRefPubMedGoogle Scholar
  20. 20.
    Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008;26:2984–91.CrossRefPubMedGoogle Scholar
  21. 21.
    Mezawa H, Sugiura T, Watanabe M, Norizoe C, Takahashi D, Shimojima A, et al. Serum vitamin D levels and survival of patients with colorectal cancer: post-hoc analysis of a prospective cohort study. BMC Cancer. 2010;10:347.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rosen GP, Beebe KL, Shaibi GQ. Vitamin D levels differ by cancer diagnosis and decline over time in survivors of childhood cancer. Pediatr Blood Cancer. 2013;60:949–52.CrossRefPubMedGoogle Scholar
  23. 23.
    Arikoski P, Komulainen J, Riikonen P, Voutilainen R, Knip M, Kröger H. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study. J Clin Endocrinol Metab. 1999;84:3174–81.CrossRefPubMedGoogle Scholar
  24. 24.
    Ruza E, Sotillo E, Sierrasesúmaga L, Azcona C, Patiño-García A. Analysis of polymorphisms of the vitamin D receptor, estrogen receptor, and collagen Ialpha1 genes and their relationship with height in children with bone cancer. J Pediatr Hematol Oncol. 2003;25:780–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Holick MF. Vitamin D: physiology, molecular biology, and clinical applications. Germany: Springer Science & Business Media; 2013.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Julie Bienertová-Vašků
    • 1
    • 3
    • 4
  • Klára Drábová
    • 3
  • Filip Zlámal
    • 1
    • 4
  • Josef Tomandl
    • 2
  • Michal Kýr
    • 3
  • Zbyněk Šplíchal
    • 1
  • Jaroslav Štěrba
    • 3
  1. 1.Department of Pathological Physiology, Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  2. 2.Department of Biochemistry, Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  3. 3.Department of Paediatric OncologyUniversity Hospital BrnoBrnoCzech Republic
  4. 4.Research Centre for Toxic Compounds in the EnvironmentMasaryk UniversityBrnoCzech Republic

Personalised recommendations